Cassava Sciences, Inc.: Business Overview, Financials & Competitive Analysis
Cassava Sciences, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with potential in rare neurological disorders, but Phase 3 Alzheimer's failure and legacy regulatory scrutiny require successful TSC pivot to justify valuation. The U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam. While the.
What is Cassava Sciences, Inc.'s industry? Cassava Sciences, Inc. (cassavasciences.com) operates in Clinical-Stage Biotechnology/Biopharmaceuticals (CNS/Neurodegenerative Disorders). AskCyborg classifies Cassava Sciences, Inc. under Clinical-Stage Biotechnology/Biopharmaceuticals (CNS/Neurodegenerative Disorders) in its company registry.
Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer's disease and tuberous sclerosis complex...
Cyborg Score thesis
Clinical-stage biotech with potential in rare neurological disorders, but Phase 3 Alzheimer's failure and legacy regulatory...
Read the full analyst-debate transcript →Get the Latest Cassava Sciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCassava Sciences, Inc. Overview
Pro stress-test →Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures. The company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer's disease or TSC.
Strategic Profile
Pro stress-test →Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The licensing of rights from Yale for the use of simufilam as a treatment for seizures related to rare neurodevelopmental disorders represents a noteworthy expansion of its therapeutic focus.
Competitive Landscape
Pro stress-test →Cassava competes in the clinical-stage Alzheimer's and neurodegeneration space with a research program centered on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles. Competitors include other CNS-focused biotechs like Annovis Bio, Anavex Life Sciences, and larger pharma pursuing traditional amyloid-targeting approaches.
Industry Context
Cassava Sciences, Inc. operates in Clinical-Stage Biotechnology/Biopharmaceuticals (CNS/Neurodegenerative Disorders).
Key facts
Founded: 1998 · Headquarters: Austin, Texas · Employees: 30 · Revenue: N/A · Market cap: $107M